close

Register today to unlock Valuecruncher and get unlimited access

  • Get unlimited access to all compartors and data
  • Save and share valuations as well as comment on others
  • Alter and save your favourite comparator companies

Already registered? Please login now

Comparison Analysis  

What's this?
Dollar1Point61
Implied share price

Sell Overvalued by 91.2%

5% margin of safety What's this?

EV / Revenue
Use Average
PLX
Protalix BioTherapeutics Inc.
AMGN
Amgen, Inc.
Change
GILD
Gilead Sciences, Inc.
Change
NVO
Novo Nordisk A/S (ADR)
Change
SNY
Sanofi SA (ADR)
Change
2.85 48.12 5.08 3.51 1.0 1.67
All amounts in millions
from last financial year
         
Implied Share Price $1.61 $82.17 $64.29 $130.98 $70.76
Market Cap 1,701 110,015 107,171 106,224 100,733
Net Debt -52 47 7,450 -19,392 7,295
Enterprise Value (EV) 1,656 110,062 114,621 108,147 58,232
Revenue 34 21,662 32,639 107,927 34,861
Balance Sheet          
Total Assets 78 71,449 51,716 91,799 102,321
Total Liabilities 82 43,366 33,182 44,830 44,272
Shareholders Equity -3 28,083 18,534 46,969 58,049.0

Where are the EBIT and EBITDA figures?

Certain companies and those in specific industries (for example insurance) do not report financial results at the EBIT or EBITDA line. For these companies where Valuecruncher does not have EBIT or EBITDA numbers we exclude the valuation metrics driven by these figures. Valuecruncher makes our other valuation metrics available for these companies.

To learn more about comparison analysis, please read our guide to comparison analysis

Comments

No comments yet. Login to comment.